Neural Therapeutics Inc. (CSE:NURL)

Neural Therapeutics Balance Sheet

Financials in millions CAD. Fiscal year is August - July.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Jan 31, 2025	Jul 31, 2024	Jul 31, 2023	Jul 31, 2022
Cash & Equivalents	0.55	0.07	0.27	0.37
Cash & Short-Term Investments	0.55	0.07	0.27	0.37
Cash Growth	678.41%	-75.56%	-26.50%	-
Other Receivables	0.01	0.03	0.07	0.05
Receivables	0.01	0.03	0.07	0.05
Prepaid Expenses	-	-	0.01	0.03
Other Current Assets	0	0	-	-
Total Current Assets	0.56	0.1	0.35	0.45
Total Assets	0.56	0.1	0.35	0.45
Accounts Payable	0.07	0.06	0.17	0.18
Accrued Expenses	0.21	0.23	0.3	0.15
Short-Term Debt	0.01	0.01	-	-
Other Current Liabilities	-	-	-	0.14
Total Current Liabilities	0.29	0.31	0.47	0.46
Long-Term Debt	0.71	0.37	0.14	-
Other Long-Term Liabilities	-	0.1	-	-
Total Liabilities	1	0.78	0.61	0.46
Common Stock	2.96	2.91	2.31	2.07
Retained Earnings	-4.35	-4.14	-3.47	-2.39
Comprehensive Income & Other	0.96	0.54	0.89	0.32
Shareholders' Equity	-0.44	-0.68	-0.26	-0.01
Total Liabilities & Equity	0.56	0.1	0.35	0.45
Total Debt	0.72	0.38	0.14	-
Net Cash (Debt)	-0.17	-0.32	0.13	0.37
Net Cash Growth	-	-	-64.04%	-
Net Cash Per Share	-0.00	-0.01	0.00	0.01
Filing Date Shares Outstanding	88.7	65.77	65.77	36.77
Total Common Shares Outstanding	67.19	65.77	45.07	36.77
Working Capital	0.27	-0.21	-0.12	-0.01
Book Value Per Share	-0.01	-0.01	-0.01	-0.00
Tangible Book Value	-0.44	-0.68	-0.26	-0.01
Tangible Book Value Per Share	-0.01	-0.01	-0.01	-0.00

Source: S&P Global Market Intelligence. Standard template. Financial Sources.